Yabao Pharmaceutical Co., Ltd. and Lilai new diabetes drug ly26082047-august clinical application
-
Last Update: 2015-03-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ren Wuxian, chairman of Yabao Pharmaceutical Co., Ltd., said on the sidelines of the two sessions of the pharmaceutical industry today that the research and development of diabetes drugs cooperated by the company and Lilly is smooth, and it is expected to apply to the State Drug Administration for clinical trials in July August this year The above diabetes drugs, ly2608204, a new diabetes drug jointly developed by Yabao pharmaceutical and Lilly, are glucokinase agonists, which can promote insulin secretion and reduce glucose production In July 2014, Yabao pharmaceutical announced a strategic partnership with Lilly to jointly develop Lilly's new diabetes drug ly2608204 The drug has completed clinical phase I and a large number of preclinical work in the United States According to the agreement signed by both parties, Yabao pharmaceutical will have the right to develop and use new drugs in China, be responsible for the financing and development of the project, while Lilly will be responsible for other markets and have the right to buy back products.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
